GlobeNewswire by notified

Luxembourg Announced as SNOMED International's Newest Member

Share

London, United Kingdom, May 24, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Agence eSanté Luxembourg are pleased to announce that Luxembourg has joined the organization as its thirty-second Member.

Luxembourg, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority. Agence eSanté, Luxembourg's national agency for the exchange and sharing of medical data, has set an overall mission to facilitate clinical information exchange both within Luxembourg and across other international actors. To work towards this reality, the agency has taken part in discussions about standardization across Europe, a contributing building block achieved with its membership in SNOMED International.

With their membership, Agence eSanté has committed their support for the use of structured clinical terminology. When applied to the health sector, interoperability ensures that information systems, and through them health professionals and patients, can communicate and trust health-related data and understand and use it in the same way. Use of SNOMED CT lends credence to the capacity of Luxembourg's health information systems to both share and ensure the meaning of the conveyed information.

SNOMED CT is the world's most comprehensive health terminology. Founded in 2007 by nine charter nations, SNOMED International is a not-for-profit, member-owned and driven international organization. The addition of Luxembourg has grown the organization's membership to thirty-three countries and territories across five continents, and will enable Luxembourg to manage and use SNOMED CT and other related products, as well as participate on the organization's General Assembly. CEO, Don Sweete, is pleased to add Luxembourg to the coalition of SNOMED International Members. "Luxembourg joins a global community of practice with shared focus, common needs, and a commitment to leveraging experiences, opportunities and challenges." He adds, "the value that results from Members working together on shared priorities can't be underestimated."

Hervé Barge, CEO of Agence eSanté, states "By introducing and adopting SNOMED CT as a clinical terminology in the context of Luxembourg's national eHealth platform, we will take further steps towards semantic interoperability of the healthcare system in Luxembourg".  Mr. Barge further states that "implementing a common referential set of medical terms is also one of the building blocks facilitating the cross-border exchange of medical data between European Member States, thus enhancing high quality and better coordinated cross-border healthcare."

Luxembourg becomes the nineteenth country in the European region to join SNOMED International, positioning the region for increased interoperability as well as the promise of leveraging learnings amongst its regional and international counterparts.

To learn more about SNOMED International and SNOMED CT, visit www.snomed.org.

To learn more about Agence eSanté Luxembourg, visit https://www.esante.lu/portal/fr/.  

 

About SNOMED International:

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world's most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation (IHTSDO.)


About Agence eSanté Luxembourg:

Agence eSanté is Luxembourg's national eHealth competence centre in charge of

  • specifying, implementing and maintaining a common interoperability platform to support electronic medical data exchange and electronic patient records on national scale
  • promoting and enhancing interoperability between healthcare information management systems
  • fostering interoperability and security in healthcare domain

It is operating the national eHealth Platform and connecting primary systems through interoperable services since 2014.    

Agence eSanté is also actively participating in European healthcare interoperability projects such as CEF eHDSI and Trillium Bridge, as well as in Euro-CAS, a project for the development of a sustainable Conformity Assessment Scheme for Europe

 

Attachment

Kelly Kuru
SNOMED International
1 416 566 8725
kku@snomed.org

Daisy Smet
Agence eSante Luxembourg
[+352] 691 31 31 40
daisy.smet@agence-esante.lu



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: SNOMED International via Globenewswire

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Atico Reports Consolidated Financial Results for 202316.4.2024 22:30:29 CEST | Press release

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the year ended December 31, 2023, posting income from mining operations of $7.4 million and a net loss of $5.8 million. Production for the year at Atico’s El Roble mine totaled 13.2 million pounds (“lbs”) of copper and 10,149 ounces (“oz”) of gold in concentrate at a cash cost(1) of $2.04 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, "we had a challenging year overall, with the first half of the year facing lower than expected head grades and lower throughput due to mechanical and operational issues, coupled with a significant appreciation in the Colombian Peso throughout the year which materially increased our costs. Despite these challenges the team did a great job getting El Roble mine back on track in the

Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program16.4.2024 22:10:00 CEST | Press release

Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan extends the anticipated cash runway to the fourth quarter of 2025, through the readout from the Phase II DOVACC trial Oslo, April 16, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several c

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations16.4.2024 22:05:00 CEST | Press release

ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations. “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families. The importance of accurately delivering this one-time gene therapy to the thalamus, while minimizing systemic exposure, is the precise use case of ClearPoint’s minimally invasive platform for gene and cell delivery,” stated Jeremy Stigall, Chief Business Officer at ClearPoin

Nokia Corporation: Repurchase of own shares on 16.04.202416.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 16 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 16.04.2024 Espoo, Finland – On 16 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL557,6403.17CEUX--BATE--AQEU--TQEX--Total557,6403.17 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Questex’s IHIF EMEA 2024 Day 2 is Full of Insightful Discussions and Partnerships16.4.2024 20:06:33 CEST | Press release

LONDON, April 16, 2024 (GLOBE NEWSWIRE) -- Day two of Questex’s International Hospitality Investment Forum EMEA (IHIF EMEA) brought deep insights into macro travel trends, supply and demand, the drivers of profit, how capital is attracted and invested, how global level deals are done and how changing trends influence what owners, brands and operators do with the customer offering. The Capital Talks panel session is one of the most eagerly anticipated spots on the programme. In a discussion moderated by Kenneth Hatton, managing director, head of hotels, Europe at CBRE, IHIF EMEA delegates learned about the underlying trends supporting hospitality investment. Representatives from KSL Capital Partners, Starwood Capital and AXA Investment Managers talked about the finer points of the current hospitality landscape. Josh Cleveland, partner & head of EMEA, real estate, StepStone Group said that hospitality’s “strong inflation hedge” had convinced the firm to invest in the asset class in an in

HiddenA line styled icon from Orion Icon Library.Eye